J B Chemicals and Pharmaceuticals Quarterly Results for Trading Insights
In Mar 2026, J B Chemicals and Pharmaceuticals (JBCHEPHARM) reported revenue ₹916 Cr and net profit ₹101 Cr — revenue -5.0% YoY. Analyse JBCHEPHARM FII DII holdings to track promoter, FII and institutional holdings.
JBCHEPHARM Quarterly Results — Revenue, Profit & EPS Highlights
J B Chemicals and Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit JBCHEPHARM screener.
- Revenue of ₹916 Cr in Mar 2026 (-16.7% vs Sept 2025, -5.0% vs Mar 2025)
- Net Profit of ₹101 Cr in Mar 2026 (-51.4% vs Sept 2025, -30.8% vs Mar 2025)
- EBITDA of ₹186 Cr in Mar 2026 (-42.8% vs Sept 2025)
- Operating Margin of 19.0% in Mar 2026 (-10.0pp vs Sept 2025)
- Earnings Per Share of ₹6.35 in Mar 2026 (-52.2% vs Sept 2025)
J B Chemicals and Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
JBCHEPHARM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 916 | 1,100 | 964 | 1,109 | 1,083 | -16.7% | -5.0% |
| Net Profit (₹ Cr) | 101 | 208 | 146 | 202 | 198 | - | - |
| EBITDA (₹ Cr) | 186 | 325 | 241 | 315 | 314 | - | - |
| EPS (₹) | 6.35 | 13.29 | 9.36 | 12.99 | 12.63 | - | - |
| Operating Margin (%) | 19.0% | 29.0% | 24.0% | 28.0% | 28.0% | - | - |
JBCHEPHARM Share Price Trend — 1-Year Movement Across Quarterly Results
J B Chemicals and Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. View JBCHEPHARM price range for the annual high/low range and current price position.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
JBCHEPHARM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
J B Chemicals and Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
All amounts in ₹ Crores